RxDoctor Payments Data

John Tapp, MD

Internal Medicine · Chattanooga, TNNPI 1811986326

Payments from drug & device makers

$10,806in general payments, 2019–2025

Across 636 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • Lilly USA, LLC$809
  • Pfizer$507
  • Amgen$497
  • plus $5K from 43 others

What the payments were for

  • Food & beverage$10,800100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,806 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$227,756
Medicare patients
474
Services billed
18,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide100$114,705
EliquisApixaban97$92,904
JardianceEmpagliflozin70$68,230
XareltoRivaroxaban59$58,901
JanuviaSitagliptin Phosphate33$34,470
JanumetSitagliptin Phos/Metformin Hcl17$19,132
Tresiba Flextouch U-200Insulin Degludec15$18,135
FarxigaDapagliflozin Propanediol14$17,140
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$15,039
LinzessLinaclotide24$12,233
Janumet XrSitagliptin Phos/Metformin Hcl14$9,573
Esomeprazole Magnesium61$7,401
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen358$7,274
MyrbetriqMirabegron12$7,049
Rosuvastatin Calcium391$6,572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,777$114,705100 claims
PfizerEliquis, Premarin$507$98,504114 claims
Boehringer IngelheimJardiance$482$68,23070 claims
MerckJanuvia, Janumet, Janumet Xr, Belsomra$334$67,87275 claims
Johnson & JohnsonXarelto$225$58,90159 claims
AstraZenecaFarxiga$1,269$17,14014 claims
GSKTrelegy Ellipta$450$15,03914 claims
AbbVieLinzess, Synthroid$1,287$14,74758 claims
Astellas Pharma US IncMyrbetriq$150$7,04912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →